Roche

Good News for Roche in Updated AIDS Treatment Guidelines

Published in AIDS Weekly, May 11th, 1998

The new formulation of Roche's HIV protease inhibitor has joined the ranks of recommended AIDS therapies.

Earlier recommendations issued by a panel of experts convened by the National Institutes of Health did not include Roche's saquinavir in its initial formulation (hard-gel capsules, trade name Invirase). But recently updated recommendations include the hard-gel version of the drug, trade name Fortovase, as well as Merck's indinavir (Crixivan), Abbott's ritonavir (Norvir), and Agouron's nelfinavir (Viracept).

And the new recommendations contain even more good news for Roche.

Based on new data (see AIDS Weekly Plus, March 30,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-05-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry